The Effect of Vitamin D3 on Metabolic Disorders in Women With Ovarian Cysts and Vitamin D Deficiency

Compare The Effect of Vitamin D3 With 2 Different Doses on Metabolic Disorders in Women With Poly-cystic Ovary Syndrome and Vitamin D Deficiency.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015100824426N1

Enrollment

124

Registered

2015-10-22

Start date

2015-05-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitamin D. Avitaminosis D

Interventions

Intervention 1: Group I: Prescription oral dose of 50,000 IU of vitamin D once per week for 8 weeks. Intervention 2: Group II: Prescription oral dose of 50,000 IU of vitamin D once per month for 2 mon

Treatment - Drugs

Group I: Prescription oral dose of 50,000 IU of vitamin D once per week for 8 weeks.

Group II: Prescription oral dose of 50,000 IU of vitamin D once per month for 2 months.

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Women with poly-cystic ovary syndrome; vitamin D less than 30 ng/ml . Exclusion Criteria: Chronic diseases such as malabsorption, chronic renal failure, cirrhosis, pancreatitis, nephrotic syndrome; malignancies; hyperprolactimenia; cushing's syndrome; congenital adrenal hyperplasia; androgen secreting tumors; using Drugs that affect metabolic parameters such as metformin, corticosteroids in the previous three months; using vitamin D and calcium and multivitamins in the last six months.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Body mass index (BMI). Timepoint: Before treatment and after completion of treatment in the eighth week. Method of measurement: By Using the formula: weight (kg) / the square of the height (m).;The level of vitamin D. Timepoint: Before treatment and after completion of treatment in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;The serum levels of triglycerides, LDL, HDL, Total cholesterol. Timepoint: Before treatment and after completion of treatment in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Fasting blood glucose levels. Timepoint: Before treatment and after completion of treatment in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Fasting insulin levels. Timepoint: Before treatment and after completion of treatment in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.	—

Measure

Time frame

Body mass index (BMI). Timepoint: Before treatment and after completion of treatment in the eighth week. Method of measurement: By Using the formula: weight (kg) / the square of the height (m).;The level of vitamin D. Timepoint: Before treatment and after completion of treatment in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;The serum levels of triglycerides, LDL, HDL, Total cholesterol. Timepoint: Before treatment and after completion of treatment in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Fasting blood glucose levels. Timepoint: Before treatment and after completion of treatment in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.;Fasting insulin levels. Timepoint: Before treatment and after completion of treatment in the eighth week. Method of measurement: Venous sampling and sent to the laboratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Moradi

Ahvaz Jundishapur University of Medical Sciences

Lmoradi16@yahoo.com+98 61 3222 2922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026